EUVIMEDEUVIMED entdecken
Übersichtsarbeit

The Potential Function of Toxoplasma gondii in Tumour Immunotherapy

Jiexing Tan iD, Zi-Guo Yuan, Luodan Yang iD, Changsheng He, Sha Wu iD, Wei Zhu, Li Gong

Immunology · 2026-08 · 178 (4) · 633-649

DOI: 10.1111/imm.70147 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Immunology, online erschienen am 10.05.2026. Verfasst von Jiexing Tan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Experimental Animal Center, Nanfang Hospital, Southern Medical University, Guangzhou, China. Hauptthemen laut MEDLINE: Toxoplasma, Immunotherapy, Neoplasms. Die Arbeit nennt 106 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Guangdong Province, President Foundation of Nanfang Hospital, Southern Medical University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immunotherapy has revolutionised the clinical treatment of many types of cancer, including immune checkpoint inhibitors, adoptive cell therapies, and tumour vaccines, which are capable of providing long‐term clinical benefit in some patients. Nevertheless, a high degree of tumour immune heterogeneity and an ongoing immunosuppressive the tumour microenvironment (TME) remain as limitations to therapeutic outcomes, and alternative methods to stimulate antitumor immunity are necessary. Given these limitations, recent researchers has been attracted to the fact that Toxoplasma gondii and its derivatives can be considered as unconventional parasite‐derived immunomodulatory vectors in cancer immunotherapy. T. gondii infection triggers strong Th1 immunity mediated on interleukin‐12 (IL‐12) and interferon‐γ (IFN‐γ), promotes dendritic cell maturation, and activates cytotoxic T cells, thus reprogramming the TME to a more immunostimulatory condition. Attenuated or metabolic‐deficient strains have shown strong antitumor efficacy in various murine tumour models by reducing tumour burden and prolonging host survival. Meanwhile, the effector proteins of the parasite, such as GRA15, GRA16, and ROP18, regulate immune cell function to induce tumour cell apoptosis, inhibit angiogenesis, and suppress metastasis. The T. gondii ‐infected cell‐derived exosomes and T. gondii lysate antigens are also immunogenic and represent safer, non‐infectious therapeutic alternatives. Here, we summarise the latest advances in the antitumor effects of T. gondii and its derivatives, focusing on immune activation, signalling regulation, direct antitumor effects, synergistic immunotherapy, potential for drug development, and challenges in future clinical translation. T. gondii and its derivatives have shown the potential to reshape TME and convert ‘cold’ tumours into ‘hot’ ones in murine cancer models. We believe that with further research in this field, the future of cancer immunotherapy will see breakthrough advancements.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ToxoplasmaImmunotherapyNeoplasmsHumansAnimalsTumor MicroenvironmentAntigens, ProtozoanCancer VaccinesDendritic Cells

Stichwörter der Autor:innen

antitumorcancerimmune responseparasitetumour microenvironment

Substanzen

Antigens, ProtozoanCancer Vaccines

Autor:innen und Institutionen

  • Experimental Animal Center, Nanfang Hospital, Southern Medical University, Guangzhou, China.
  • Provincial Key Laboratory of Zoonosis Prevention and Control, College of Veterinary Medicine, South China Agricultural University, Guangzhou, China.
  • Laboratory of Exercise and Neurobiology, College of Physical Education and Sports Science, South China Normal University, University Town, Guangzhou, China.
  • Department of Immunology, School of Basic Medical Sciences, Southern Medical University, Guangdong Provincial Key Laboratory of Proteomics, Guangzhou, China.
  • Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou 510000, China;, Guangzhou, China.
  • State Key Laboratory of Organ Failure Research; Key Laboratory of Infectious Diseases Research in South China (Southern Medical University), Ministry of Education; Guangdong Provincial Key Laboratory for Prevention and…

ORCID-Profile: Jiexing Tan, Luodan Yang, Sha Wu

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Guangdong Province
  • President Foundation of Nanfang Hospital, Southern Medical University

Zitieren

APA

Tan, J., Yuan, Z. G., Yang, L., He, C., Wu, S., Zhu, W., & Gong, L. (2026). The Potential Function of Toxoplasma gondii in Tumour Immunotherapy. Immunology, 178(4), 633-649. https://doi.org/10.1111/imm.70147

Vancouver

Tan J, Yuan ZG, Yang L, He C, Wu S, Zhu W, et al. The Potential Function of Toxoplasma gondii in Tumour Immunotherapy. Immunology. 2026;178(4):633-649. doi:10.1111/imm.70147

BibTeX
@article{Tan2026,
  author = {Tan, Jiexing and Yuan, Zi-Guo and Yang, Luodan and He, Changsheng and Wu, Sha and Zhu, Wei and Gong, Li},
  title = {The Potential Function of Toxoplasma gondii in Tumour Immunotherapy},
  journal = {Immunology},
  year = {2026},
  volume = {178},
  number = {4},
  pages = {633--649},
  doi = {10.1111/imm.70147}
}
Kostenlos starten →